Search Results for "ATTR"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

RNAi Therapy in ATTRv Amyloidosis with Polyneuropathy (HELIOS-A): Patient-reported Experiences and Preferences

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Meta-regression analysis of the association between change in six minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy

Likelihood of disease worsening in patients receiving tafamidis for ATTR amyloidosis with cardiomyopathy (ATTR-CM): A targeted literature review

The Journey to Diagnosis of ATTR Amyloidosis: Burden of Early Disease

Unmet Need in a Contemporary Cohort of Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy Patients

Neurofilament Light Chain in ATTR Amyloidosis with Cardiomyopathy: Analysis from the Phase 3 APOLLO-B Study

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

The Journey to Diagnosis of Wild-Type ATTR Amyloidosis: A Path with Multisystem Involvement

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.